期刊文献+

国产多极消融导管对醋酸脱氧皮质酮诱导高血压模型猪下丘脑炎症反应及交感活性的抑制作用 被引量:2

Inhibition of hypothalamus inflammatory and sympathetic system reaction in DOCA induced hypertension model by renal denervation with a multi-electrode ablation system
下载PDF
导出
摘要 目的探讨国产多极消融导管对醋酸脱氧皮质酮(DOCA)诱导高血压模型猪下丘脑炎症反应及交感活性的抑制作用.方法研究入选12头3月龄的实验动物猪分为三组,分别为DOCA诱导的高血压模型+RDN消融组、DOCA诱导的高血压模型+假手术组和正常对照组,每组4头.DOCA诱导的高血压模型消融组采用自主研发的国产Spark多极消融导管对其进行肾动脉去神经消融术.术后1个月随访三组实验动物的平均动脉压(MAP),通过Elisa方法和荧光免疫组化方法分析下丘脑炎性因子、交感兴奋相关蛋白的表达水平.结果DOCA高血压模型消融组术后MAP显著降低[(141.25±2.60)mm Hg比(120.38±2.46)mm Hg,P<0.001];DOCA诱导高血压模型消融组与DOCA诱导高血压模型假手术组比较,下丘脑白介素-6(IL-6)水平[(9.60±1.81)ng/ml比(4.52±0.32)ng/ml,P=0.009]及肿瘤坏死因子-α(TNF-α)水平[(10.92±0.51)pg/ml比(1.37±1.02)pg/ml,P<0.001]显著降低;下丘脑c-Fos蛋白表达比例[(8.03±0.69)%比(15.75±1.47)%,P=0.011]及Fos-B蛋白的表达比例[(16.70±0.49)%比(37.52±0.70)%,P<0.001)]与假手术组比较,RDN消融组均显著降低.结论国产Spark多极消融导管进行肾动脉去神经消融术后能够有效降低DOCA诱导的高血压模型猪的平均动脉压.同时对于该模型的中枢下丘脑炎症反应及交感神经兴奋性均具有抑制作用. Objective To investigate the inhibition of hypothalamus inflammatory and sympathetic system reaction in deoxycortone acetate(DOCA)induced hypertension model by renal denervation(RDN)with a multielectrode ablation system.Methods 12 Bama pigs were randomly assigned to 3 groups:Control group(n=4),DOCA induced hypertension+Sham group(n.=4)and DOCA induced hypertension+RDN group(n.=4).1 month after the operation,the mean blood pressure,expression of inflammatory factors and sympathetic system related proteins in hypothalamus were tested by Elisa and fluorescence immunity.Results MAP in DOCA induced hypertension+RDN group was significantly reduced[(141.25±2.60)mm Hg vs.(120.38±2.46)mm Hg,P<0.001].Meanwhile inflammatory factors as IL-6[(9.60±1.81)ng/ml vs.(4.52±0.32)ng/ml,P=0.009]and TNF-a[(10.92±0.51)pg/ml vs.(1.37±1.02)pg/ml,P<0.001]were also attenuated in DOCA induced hypertension+RDN group.The sympathetic system related proteins in hypothalamus as c-Fos[(8.03±0.69)%vs.(15.75±1.47)%,P=0.011]and Fos-B[(16.70±0.49)%vs.(37.52±0.70)%,P<0.001)]showed lower expression in DOCA induced hypertension+RDN group.Conclusion RDN proceeded by multi-electrode ablation catheter could attenuate MAP of DOCA induced hypertension.Inhibition of the inflammatory reaction and over reaction of sympathetic system could be the possible mechanism of this procedure.
作者 韩文正 干倩 王鸣 翟馨蓉 曲新凯 关韶峰 HAN Wen-zheng;GAN Qian;WANG Ming;ZHAI Xin-rong;QU Xin-kai;GUAN Shao-feng(Department of Cardiology,Huadong Hospital Afflicted to Fudan University,Shanghai Key Laboratory of Clinical Geriatric Medicine,Shanghai 200040,China)
出处 《中国心血管病研究》 CAS 2020年第5期435-440,共6页 Chinese Journal of Cardiovascular Research
基金 国家自然科学基金项目面上项目(81370361)。
关键词 经皮肾动脉去神经术 交感神经 FOS蛋白 炎症反应 Renal denervation Sympathetic system Fos protein family Inflammatory reaction
  • 相关文献

参考文献1

二级参考文献23

  • 1Vongpatanasin W. Resistant hypertension: a review of diag- nosis and management. JAMA 2014; 311: 2216-2224.
  • 2Persell S. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011; 57: 1076-1080.
  • 3Vink EE, Blankestijn PJ. Evidence and consequences of the central role of the kidneys in the pathophysiology of sympa- thetic hyperactivity. Front Physio12012; 3: 29.
  • 4Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-1281.
  • 5Krum H, Schlaich M, Whitboum R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: du- rability of blood pressure reduction out to 24 months. Hyper- tension 2011; 57:911-917.
  • 6Krum H, Schlaich MP, Bohm M, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 2014; 383: 622-629.
  • 7Syrnplicity HTN-2 Investigators, Esler MD, Krum H, et al. Renal sympathetic denervation in patients with treat- ment-resistant hypertension (The Symplicity HTN-2 Trial): a randomized controlled trial. Lancet 2010; 376: 1903-1909.
  • 8Esler MD, Krum H, Schlaich M, et al. Renal sympathetic denervation for treatment of drug-resistant hypertension. One-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation 2012; 126: 2976-2982.
  • 9Azizi M, Sapoval M, Gosse P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 2015; 385: 1957-1965.
  • 10Kandzari DE, Bhatt DL, Sobotka PA, et al. Catheter-based renal denervation for resistant hypertension: rationale and de- sign of the Symplicity HTN-3 Trial. Clin Cardiol 2012; 35: 528-535.

同被引文献23

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部